{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458275293
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[Beta-amyloid]] (Aβ40/42)
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = Investigational
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 1043556-46-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4DF060P933
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09680
<!-- Chemical data -->
| C=6496 | H=10072 | N=1740 | O=2024 | S=42
| molecular_weight = 146.3 kg/mol (peptide)
}}

'''Gantenerumab''' is a [[monoclonal antibody]] for the treatment of [[Alzheimer's disease]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/gantenerumab.pdf Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab] ''American Medical Association''.</ref><ref>[http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], ''World Health Organization''.</ref> A phase I [[clinical trial]] has been conducted in 2006/07.<ref>{{ClinicalTrialsGov|NCT00531804|A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease}}</ref>

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.<ref>http://www.scarletroadstudy.com/en-CA/index.aspx</ref> 

One clinical study was stopped on December 19, 2014 after disappointing results.<ref>http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045</ref>

As of late 2014, Phase III clinical trials are ongoing.<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 10 November 2014| title = Neue Wirkstoffe – Gantenerumab| journal = Österreichische Apothekerzeitung| issue = 23/2014| page = 55| language = German}}</ref>

== References ==
<references/>

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{nervous-system-drug-stub}}